Outcomes of rescue therapy in acute severe ulcerative colitis: Data from the United Kingdom inflammatory bowel disease audit

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 8, 2013, Pages 935-945

  Lynch, R W ^a   Lowe, D ^b   Protheroe, A ^b   Driscoll, R ^c   Rhodes, J M ^d   Arnott, I D R ^a,b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^c Crohn's and Colitis UK Leeds and District Group   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; INFLIXIMAB; STEROID;

ACUTE SEVERE ULCERATIVE COLITIS; ADULT; AGE; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; COLON SURGERY; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STEROID THERAPY; ULCERATIVE COLITIS; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL AUDIT; COHORT STUDIES; COLITIS, ULCERATIVE; CYCLOSPORINE; FEMALE; GREAT BRITAIN; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; STEROIDS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884910652     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12473     Document Type: Article

References (28)

1. Podolsky DK,. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
2. Molodecky NA, Soon IS, Kaplan GG, et al,. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.
3. Edwards FC, Truelove SC,. The course and prognosis of ulcertive colitis. Gut 1963; 4: 299-315.
4. Gulliford SR, Limdi JK,. Acute severe ulcerative colitis: timing is everything. Postgrad Med J 2011; 87: 215-22.
5. Dinesen LC, Walsh AJ, Travis SP, et al,. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010; 4: 431-7.
6. Truelove SC, Witts LJ,. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954; 2: 375-8.
7. Gallagher ND, Goulston SJ, Morrow W, et al,. The management of fulminant ulcerative colitis. Gut 1962; 3: 306-11.
8. Truelove SC, Jewell DP,. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-70.
9. Turner D, Walsh CM, Griffiths AM, et al,. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-10.
10. Stenner JMC, White P, Gould SR,. Audit of the management of severe ulcerative colitis in a DGH. Gut 2001; 48: A87.
11. Roberts SE, Williams JG, Goldacre MJ, et al,. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ 2007; 335: 1033.
12. Nicholls RJ, Clark DN, Satsangi J, et al,. Nationwide linkage analysis in Scotland implicates age as the critical overall determinant of mortality in ulcerative colitis. Aliment Pharmacol Ther 2010; 31: 1310-21.
13. Lichtiger S, Present DH, Hanauer S, et al,. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5.
14. Actis GC, Fadda M, Sapino A, et al,. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007; 7: 13.
15. Arts J, D'Haens G, Rutgeerts P, et al,. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 73-8.
16. Moskovitz DN, Van Assche G, Rutgeerts P, et al,. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 760-5.
17. Järnerot G, Hertervig E, Curman B, et al,. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.
18. Lees CW, Heys D, HO GT, et al,. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 411-9.
19. Laharie D, Bourreille A, Branche J, et al,. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-15.
20. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6.
21. Järnerot G, Rolny P, Sandberg-Gertzén H,. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-13.
22. Travis SP, Farrant JM, Jewell DP, et al,. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
23. Croft A, Walsh A, Doecke J, et al,. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs infliximab. Aliment Pharmacol Ther 2013; 38: 294-302.
24. Durai D, Hawthorne AB,. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005; 22: 907-16.
25. Ho GT, Mowat C, Satsangi J, et al,. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 1079-87.
26. Järnerot G,. How to judge the response to treatment in ulcerative colitis? Inflamm Bowel Dis 2008; 14 (Suppl. 2): S222-3.
27. Travis S, Satsangi J, Lémann M,. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut 2011; 60: 3-9.
28. Health Protection Agency. Summary Points on Clostridum Difficile Infection. July 2012. Available at: http://www.hpa.org.uk/web/ HPAweb&HPAwebStandard/HPAweb-C/1195733750761.